Supporting our clinical observations in patients with NASH, we found that GLP-1R agonist (exendin-4) significantly reduced hepatic DNL (as measured by the incorporation of 14C-acetate into cellular lipid) in both hepatoma cell lines and primary cultures of human hepatocytes. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.